Research Analysts Issue Forecasts for Monte Rosa Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Investment analysts at Wedbush issued their FY2023 earnings estimates for Monte Rosa Therapeutics in a report released on Wednesday, February 14th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($2.63) per share for the year. Wedbush currently has a “Outperform” rating and […]

Related Keywords

Canada , ,Monte Rosa Therapeutics Inc ,Barclays Plc ,Sg Americas Securities ,Royal Bank ,Life Insurance Co ,Nasdaq ,Ameritas Investment Partners Inc ,Monte Rosa Therapeutics ,Free Report ,Monte Rosa Therapeutic ,Rosa Therapeutics ,Investment Partners ,Get Free Report ,Monte Rosa Therapeutics Daily ,Nasdaq Glue ,Glue ,Medical ,Earnings Estimates ,Wedbush ,